Global Hydroxycarbamide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hydroxycarbamide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Hydroxycarbamide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hydroxycarbamide market is projected to reach US$ 342.7 million in 2034, increasing from US$ 233 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2034. Demand from Sickle Cell Disease and Cancer are the major drivers for the industry.
Global Hydroxycarbamide key players include Qilu Pharmaceutical, Beijing Jialin Pharma, Taj Pharma, etc. Global top three manufacturers hold a share over 35%.
Asia-Pacific is the largest market, with a share nearly 60%, followed by Europe, and North America, both have a share about 40 percent.
In terms of product, Capsule is the largest segment, with a share over 60%. And in terms of application, the largest application is Sickle Cell Disease, followed by Cancer, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hydroxycarbamide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bristol Myers Squibb
Taj Pharma
Beijing Jialin Pharma
Qilu Pharmaceutical
Teva Pharma
Cipla
Zydus Cadila
United Biotech
Par Pharma
Khandelwal Laboratories
Alkem (Cytomed)
Samarth Pharma
VHB Life Sciences
Segment by Type
Capsule
Tablet
Sickle Cell Disease
Cancer
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Hydroxycarbamide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Hydroxycarbamide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Hydroxycarbamide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Hydroxycarbamide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Hydroxycarbamide introduction, etc. Hydroxycarbamide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Hydroxycarbamide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Hydroxycarbamide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hydroxycarbamide market is projected to reach US$ 342.7 million in 2034, increasing from US$ 233 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2034. Demand from Sickle Cell Disease and Cancer are the major drivers for the industry.
Global Hydroxycarbamide key players include Qilu Pharmaceutical, Beijing Jialin Pharma, Taj Pharma, etc. Global top three manufacturers hold a share over 35%.
Asia-Pacific is the largest market, with a share nearly 60%, followed by Europe, and North America, both have a share about 40 percent.
In terms of product, Capsule is the largest segment, with a share over 60%. And in terms of application, the largest application is Sickle Cell Disease, followed by Cancer, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hydroxycarbamide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bristol Myers Squibb
Taj Pharma
Beijing Jialin Pharma
Qilu Pharmaceutical
Teva Pharma
Cipla
Zydus Cadila
United Biotech
Par Pharma
Khandelwal Laboratories
Alkem (Cytomed)
Samarth Pharma
VHB Life Sciences
Segment by Type
Capsule
Tablet
Segment by Application
Sickle Cell Disease
Cancer
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Hydroxycarbamide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Hydroxycarbamide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Hydroxycarbamide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Hydroxycarbamide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Hydroxycarbamide introduction, etc. Hydroxycarbamide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Hydroxycarbamide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices